NO20010920L - Stabil hypoksi induserbar faktor-1<alfa> og anvendelsesmetoder - Google Patents

Stabil hypoksi induserbar faktor-1<alfa> og anvendelsesmetoder

Info

Publication number
NO20010920L
NO20010920L NO20010920A NO20010920A NO20010920L NO 20010920 L NO20010920 L NO 20010920L NO 20010920 A NO20010920 A NO 20010920A NO 20010920 A NO20010920 A NO 20010920A NO 20010920 L NO20010920 L NO 20010920L
Authority
NO
Norway
Prior art keywords
alpha
inducible factor
hypoxia
mutein
stable
Prior art date
Application number
NO20010920A
Other languages
English (en)
Norwegian (no)
Other versions
NO20010920D0 (no
Inventor
Gregg L Semenza
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Publication of NO20010920D0 publication Critical patent/NO20010920D0/no
Publication of NO20010920L publication Critical patent/NO20010920L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Manufacturing Of Steel Electrode Plates (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
NO20010920A 1998-08-25 2001-02-23 Stabil hypoksi induserbar faktor-1<alfa> og anvendelsesmetoder NO20010920L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/148,547 US6124131A (en) 1998-08-25 1998-08-25 Mutant hypoxia inducible factor-1 HIF-1
PCT/US1999/019416 WO2000010578A1 (fr) 1998-08-25 1999-08-25 Facteur-1 alpha stable inductible en hypoxie et procede d'utilisation

Publications (2)

Publication Number Publication Date
NO20010920D0 NO20010920D0 (no) 2001-02-23
NO20010920L true NO20010920L (no) 2001-04-23

Family

ID=22526230

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010920A NO20010920L (no) 1998-08-25 2001-02-23 Stabil hypoksi induserbar faktor-1<alfa> og anvendelsesmetoder

Country Status (11)

Country Link
US (3) US6124131A (fr)
EP (1) EP1107768B1 (fr)
JP (1) JP2002523028A (fr)
AT (1) ATE344043T1 (fr)
AU (1) AU758627B2 (fr)
CA (1) CA2340328C (fr)
DE (1) DE69933877T2 (fr)
IL (2) IL141494A0 (fr)
NO (1) NO20010920L (fr)
NZ (1) NZ510002A (fr)
WO (1) WO2000010578A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ504847A (en) * 1997-12-04 2003-02-28 Genzyme Corp Chimeric protein comprising a hypoxia inducible factor protein and a transcriptional activation domain and pharmaceutical use
US6124131A (en) * 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1
FR2801319A1 (fr) * 1999-11-18 2001-05-25 Inst Nat Sante Rech Med Construction d'acide nucleique porteuse d'un systeme regulant l'expression d'un gene
JP2004536552A (ja) * 2000-08-07 2004-12-09 アンジオジェネティクス・スウェーデン・エイ・ビー フォン・ヒッペル・リンドウ腫瘍抑制タンパク質による低酸素誘導因子−１の条件付き調節のメカニズム
US7285414B2 (en) * 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
US20040101825A1 (en) * 2001-09-26 2004-05-27 Van Meir Erwin G. Viruses targeted to hypoxic cells and tissues
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US6878729B2 (en) 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
WO2002089854A1 (fr) 2001-05-09 2002-11-14 Anges Mg, Inc. Transfert de genes et facteur angiogenique pour maladie de la peau
WO2002094862A2 (fr) * 2001-05-23 2002-11-28 Angiogene Inc. Facteurs activant l'hypoxie et utilisation de ces facteurs pour activer l'angiogenese et ameliorer les fonctions musculaires
US6838430B2 (en) 2001-09-28 2005-01-04 The Regents Of The University Of California Use of HIF-1a variants to accelerate wound healing
US20030093147A1 (en) * 2001-11-13 2003-05-15 Ogle Matthew F. Medical devices that stimulate growth factor production
CN102552262A (zh) * 2001-12-06 2012-07-11 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
US7053046B2 (en) * 2001-12-21 2006-05-30 Mcgrath Kevin Peptide activators of VEGF
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
RU2346688C2 (ru) * 2002-12-06 2009-02-20 Фиброген, Инк. Регулирование содержания жира
CN100469370C (zh) * 2002-12-06 2009-03-18 法布罗根股份有限公司 一种稳定HIFα的制剂在制备调节脂肪代谢的药物中的应用
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
CN1921892A (zh) * 2003-10-17 2007-02-28 艾克蒂斯生物公司 用于治疗癌症的msp36的慢病毒载体传递
JP2007510734A (ja) * 2003-11-07 2007-04-26 ザ ヘンリー エム． ジャクソン ファウンデイション 低酸素誘導性遺伝子発現の活性化
CA2546649A1 (fr) * 2003-11-26 2005-06-16 Entelos, Inc. Traitement de la polyarthrite rhumatoide au moyen d'antagonistes du facteur 1.alpha. inductible par hypoxie
US20050137568A1 (en) * 2003-12-17 2005-06-23 Jones Donald K. Activatable bioactive implantable medical device and method of use
US7294123B2 (en) * 2003-12-17 2007-11-13 Corris Neurovascular, Inc. Activatable bioactive vascular occlusive device and method of use
WO2005065309A2 (fr) * 2003-12-31 2005-07-21 Actis Biologics, Inc. Administration par vecteur de lentivirus de igfbp-3 natif ou mute pour traiter un cancer
US7247159B2 (en) * 2004-04-08 2007-07-24 Cordis Neurovascular, Inc. Activatable bioactive vascular occlusive device
WO2006009843A2 (fr) * 2004-06-18 2006-01-26 The Johns Hopkins University Regulation negative du facteur 1 induisant l'hypoxie par os-9
CN1319525C (zh) * 2004-09-16 2007-06-06 北京圣医耀科技发展有限责任公司 紫杉醇－海藻酸钠微球血管栓塞剂及其制备
US20090304650A1 (en) * 2005-05-11 2009-12-10 Scott Edward W Repair of the Bone Marrow Vasculature
ATE470439T1 (de) * 2005-06-15 2010-06-15 Fibrogen Inc Verwendung von hif 1alfa modulatoren zur behandlung von krebs
GB0520176D0 (en) * 2005-10-04 2005-11-09 Imp College Innovations Ltd Use
US20090215687A1 (en) 2005-10-21 2009-08-27 Cornell Research Foundation, Inc. Compounds for Enhancing Hypoxia Inducible Factor Activity and Methods of Use
EP2005753B1 (fr) * 2006-03-30 2016-12-21 LG Electronics, Inc. Procédé et dispositif de codage/décodage d'un signal vidéo multivue
US7759306B2 (en) * 2006-05-16 2010-07-20 Simoni Jan S Methods of treating acute blood loss
CA2658972C (fr) 2006-07-31 2019-11-26 Vascular Biogenics Ltd. Polypeptides et polynucleotides les codant et leur utilisation dans le traitement d'affections medicales associees a l'ischemie
US20080081354A1 (en) * 2006-10-02 2008-04-03 Cardiac Pacemakers, Inc. Devices, vectors and methods for inducible ischemia cardioprotection
CN105770910A (zh) 2006-10-03 2016-07-20 建新公司 肌萎缩性侧索硬化症和其它脊髓病症的基因治疗
KR100992526B1 (ko) * 2007-11-21 2010-11-05 한국과학기술연구원 이황화결합을 이용한 내열성의 알파-1-안티트립신 뮤테인및 그의 제조방법
US9446031B2 (en) 2012-01-18 2016-09-20 National University Of Singapore Compositions and methods for neovascularization
WO2017027810A2 (fr) * 2015-08-12 2017-02-16 The General Hospital Corporation Compositions et méthodes qui favorisent l'hypoxie ou la réponse hypoxique pour le traitement et la prévention d'un dysfonctionnement mitochondrial et de troubles du stress oxydatif
WO2020146758A1 (fr) 2019-01-10 2020-07-16 The General Hospital Corporation Méthodes de traitement de dysfonctionnements ou de maladies associés aux mitochondries

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882914A (en) * 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
US6099832A (en) * 1997-05-28 2000-08-08 Genzyme Corporation Transplants for myocardial scars
NZ504847A (en) 1997-12-04 2003-02-28 Genzyme Corp Chimeric protein comprising a hypoxia inducible factor protein and a transcriptional activation domain and pharmaceutical use
US6124131A (en) * 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1

Also Published As

Publication number Publication date
WO2000010578A1 (fr) 2000-03-02
NO20010920D0 (no) 2001-02-23
US6562799B1 (en) 2003-05-13
EP1107768A4 (fr) 2004-12-29
US6124131A (en) 2000-09-26
EP1107768A1 (fr) 2001-06-20
AU5691499A (en) 2000-03-14
IL141494A (en) 2009-05-04
DE69933877T2 (de) 2007-06-21
JP2002523028A (ja) 2002-07-30
IL141494A0 (en) 2002-03-10
EP1107768B1 (fr) 2006-11-02
NZ510002A (en) 2003-11-28
AU758627B2 (en) 2003-03-27
DE69933877D1 (de) 2006-12-14
CA2340328C (fr) 2011-06-21
ATE344043T1 (de) 2006-11-15
US20030176349A1 (en) 2003-09-18
CA2340328A1 (fr) 2000-03-02

Similar Documents

Publication Publication Date Title
NO20010920D0 (no) Stabil hypoksi induserbar faktor-1&lt;alfa&gt; og anvendelsesmetoder
ATE31625T1 (de) Pharmazeutisches mittel zur behandlung des diabetes mellitus.
Ingimarsson et al. Side effects of long-term treatment with human leukocyte interferon
DK1214937T3 (da) Terfenadincarboxylat og behandling af hudirritation
KR950700333A (ko) 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로부터의 제조 방법(improved alpha interferon composition and method for its production from human peripheral blood leukocytes)
CO4970691A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
ES2043890T3 (es) Nuevo uso medico.
LU91544I2 (fr) Alpha alglucosidase
LV10180A (lv) Farmaceitiska kompozicija
NO955189L (no) En forkortet keratinocyt vekstfaktor (KGF) med ökende biologisk aktivitet
FI103180B (fi) Flurbiprofeenia sisältävien lääkkeiden valmistus kipujen ja/tai tulehd usten torjumiseksi eläimissä ja ihmisissä
PT950057E (pt) Enantiomeros de 3-piridilo e sua utilizacao como analgesicos
EP0151989A3 (en) Means for the treatment of cardiac diseases
MY102806A (en) Human interleukin-3 and muteins thereof
DE68926679D1 (de) Physiologisch aktives polypeptid, rekombinantes plasmid, rekombinante mikrobielle zellen, medizinisches präparat sowie verfahren zur gewinnung des gereinigten polypeptids
ATE187642T1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
FI885807L (fi) Puhdistetun, biologisesti aktiivisen, bakteerien avulla tuotetun rekombinanttisen ihmis- CSF-1:n tuottaminen
DK0817646T3 (da) Fremgangsmåder til behandling af inflammation og præparater derfor
Silverman et al. Activation of herpes simplex following dermabrasion: report of a patient successfully treated with intravenous acyclovir and brief review of the literature
IT8224624A0 (it) Sale metilglucamminico del flurbiprofen dotato di attivita&#39;terapeutica e procedimento per lasua preparazione.
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
ATE206056T1 (de) Therapeutisches agens für neutropenie
DK277387A (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
PT1016414E (pt) Hormona de crescimento humano para estimular a hematopoiese e a reconstituicao imnologica apos transplante de celulas estaminais hematopoieticas em humanos
NO960866D0 (no) Fremgangsmåte til behandling av leversykdom og lignende indikasjoner med vasodilaterende midler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application